Glycogen Branching Enzyme Deficiency (GBED)
Gene or Region: GBE1
Reference Variant: C
Mutant Variant: A
Affected Breeds: Quarter Horses and Paint Horses
Research Confidence: High - Findings reproduced in multiple studies
Explanation of Results: gbed/gbed = homozygous for Glycogen Branching Enzyme Deficiency, trait expressed gbed/n = heterozygous for Glycogen Branching Enzyme Deficiency, carrier n/n = no variant detected
General Description
Glycogen branching enzyme deficiency is a lethal recessive disorder characterized by seizures, muscle weakness, respiratory failure, and death. Many affected foals do not make it full term and are aborted or stillborn. Carriers (gbed/n) have no known issues. This disorder is analogous to glycogen storage disease type IV in humans and Norwegian forest cats. Studies have indicated that between 4-11% of registered American Quarter Horses and American Paint Horses carry the GBED mutation.
Gene Information
GBE1 is an enzyme involved in the conversion between glucose and glycogen. Both stored glycogen and mobilized glucose are vital for normal physiological functions. Glycogen storage disorders have been documented in many species. The GBED mutation results in a premature stop codon that severely truncates the produced protein.
References
Ward TL et al., “Glycogen branching enzyme (GBE1) mutation causing equine glycogen storage disease IV.” (2004) Mamm Genome. 15: 570-7. PMID: 15366377
Wagner ML et al., “Allele frequency and likely impact of the glycogen branching enzyme deficiency gene in Quarter Horse and Paint Horse populations.” (2006) J Vet Intern Med. 20: 1207-11. PMID: 17063718
Tryon RC et al., “Evaluation of allele frequencies of inherited disease genes in subgroups of American Quarter Horses.” (2009) J Am Vet Med Assoc. 234: 120-5. PMID: 19119976
More Horse Health
Equine Recurrent Uveitis Risk and Severity
Equine Recurrent Uveitis (ERU) is the most common cause of blindness in horses, affecting about 3-15% of the horse population worldwide. Characterized by episodes of inflammation of the middle layer of the eye, Equine Recurrent Uveitis in horses leads to the development of cataracts, glaucoma and eventually complete loss of vision.
Foal Immunodeficiency Syndrome
Foal immunodeficiency syndrome (FIS) is a failure in the development of the adaptive immune system. At 3-6 weeks of age, once the maternal antibodies begin to degrade, foals exhibit signs of anemia, diarrhea, and pneumonia. As these foals fail to respond to treatment for infections, they are humanely euthanized at a young age.
Glanzmann Thrombasthenia
Glanzmann Thrombasthenia (GT) is a blood platelet function disorder, resulting from a reduction in the platelet fibrinogen receptor protein. Clinical signs can be characterized by bleeding on the skin or from the mouth/nostril/gastrointestinal mucosas, and may include skin rashes with blood spots under the skin, nasal bleeding, gastrointestinal and gingival bleedings.
Hereditary Equine Regional Dermal Asthenia
Hereditary Equine Regional Dermal Asthenia (HERDA) is a degenerative skin disease that primarily affects the American Quarter Horse. Loose skin is often an early indication of the disease, and severe seromas, hematomas, ulcerations usually develop around 1.5 years of age. There is no cure, and the majority of affected animals have to be euthanized within 2-4 years.